

Lista lucrări științifice

1. Ciuleanu TE, Ciuleanu Elisabeta, Cebotaru Cristina, Rădulescu Ioana, **Kacsó G.** Monitorizarea trialurilor clinice. Radioterapie & Oncologie Medicală, 1998; 4: 114-117.
2. **Kacsó G**, Cernea V. Radiochimioterapia în cancerele sferei ORL - un nou standard terapeutic? Radioterapie & Oncologie Medicală, 1999; 4: 319-330.
3. **Kacsó G**, Cernea V. Radioterapia în anul 2000: prezent și perspective. Radioterapie & Oncologie Medicală, 2000; 1: 54-64.
4. **Kacsó G**, Turcu C. Este radioterapia sau chirurgia esențială în tratamentul gliomelor cu grad redus de malignitate? Radioterapie & Oncologie Medicală 2000; 2: 172- 180.
5. **Kacsó G.** Educația medicală continuă. Radioterapie & Oncologie Medicală, 2000; 4: 339- 343.
6. **Kacsó G.** Radioterapia cancerului de col uterin: aportul imagisticii (RMN, CT) în planul de tratament. Radioterapie & Oncologie Medicală, 2000; 2: 207- 208.
7. Cernea V, **Kacsó G**, Coza O, Ghilezan N, Todor N. Dose intensity and the therapeutic ratio in the radiotherapy of advanced laryngeal cancer. Radioterapie & Oncologie Medicală, 2001; 2: 163- 167.
8. **Kacsó G**, Martin D, Boboc G et al. Long term results and pattern of failure after radiotherapy alone for larynx carcinoma. Radioterapie & Oncologie Medicală, 2001; 2: 168- 175.
9. **Kacsó G.** Curieterapia- o opțiune reală pentru România? Radioterapie & Oncologie Medicală, 2002; 3: 161- 171.
10. Marcy PY, Bailet C, Foa C, Benezery K, **Kacsó G.** Coeliac plexus neurolysis under ultrasound guidance with contrast agents: tips and tricks. Eurorad Interventional Radiology, 2002; 1452:1-7 (BDI).
11. **Kacsó G.** Raport asupra celei de-a 21-a reuniuni anuale ESTRO- Praga 17- 21 septembrie 2002. Radioterapie & Oncologie Medicală, 2002; 4: 271- 273.
12. **Kacsó G.** Radiobiologia curieterapiei interstițiale. Radioterapie & Oncologie Medicală, 2003; 1: 5- 13.
13. Cernea D, **Kacsó G**, Stan A. Radiochimioterapia în tumorile cerebrale cu grad ridicat de malignitate. Experiența Institutului Oncologic Cluj 1995- 2001. Radioterapie & Oncologie Medicală 2003; 1: 33- 38.
14. Resiga L, Olinici CD, **Kacsó G.** Carcinomul nediferențiat gastric cu stroma limfoidă. Prezentare de caz și analiza literaturii. Radioterapie & Oncologie Medicală 2003; 1: 53-56.
15. **Kacsó G**, Cebotaru C, et al. Radiochimioterapia în cancerele tranziționale infiltrative ale vezicii urinare: experiența IOC 1991-2001. Radioterapie & Oncologie Medicală 2004; 1: 40- 46.
16. **Kacsó G**, Rancea A, Spârchez Z et al. Curieterapia în cancerul de endometru- implicații în modificarea ghidului therapeutic. Radioterapie & Oncologie Medicală 2004; 4: 274- 278.
17. **Kacsó G**, Hannoun- Levi JM, Marcie S et al. Permanent Iodine 125 Brachytherapy as curative option for organ confined prostate cancer - toxicity and short term biochemical outcome. Radioterapie & Oncologie Medicală, 2005; 1: 38- 45
18. Sârb DI, Feciche B, **Kacsó G**, Coman I. Rezeecția transuretrală iterativă a tumorilor vezicale în experiența noastră. Quo vadis, 2006; 8: 1- 4.

19. Mihailov A, Munteanu A, **Kacsó G** et al. Managementul toxicității în radiochimioterapia concomitentă în tumorile digestive. *Radioterapie & Oncologie Medicală*, 2006;2: 115- 120.
20. Vereșezan O, **Kacsó G**, Neamțu Șt, Ciuce C. Brahiterapia interstițială în sarcoamele de părți moi. Particularități tehnice la copii. *Radioterapie & Oncologie Medicală*, 2006; 2: 127- 130.
21. Brie I, Virag P, Perde-Schrepler M, **Kacsó G**, Nagy V. Studiul relației între radiosensibilitatea in vitro a limfocitelor și radiosensibilitatea clinică a țesuturilor normale la pacienți cu cancer de col uterin supuse radioterapiei. *Radioterapie & Oncologie Medicală* 2007; 1: 49- 57.
22. Burz C, **Kacsó G**. Durerea de cauză oncologică- ignoranță sau neputință. *Radioterapie & Oncologie Medicală*, 2007; 2: 137- 144.
23. Zs. Fekete, M. Mureșan, **G. Kacsó**. Radiochimioterapia cu supraimpresiune prin brahiterapie ca tratament curativ al carcinomului epidermoid avansat locoregional de canal anal. Prezentare de caz și revista literaturii. *Radioterapie & Oncologie Medicală*, 2007; 2: 170- 174.
24. **Kacsó G**, Căinap C. Actualități în cancerele urologice. *Radioterapie & Oncologie Medicală*, 2007; 3: 244 – 247.
25. Căinap C, **Kacsó G**. Indicații de utilizare clasice și noi ale markerilor tumorali. *Radioterapie & Oncologie Medicală*, 2007; 3: 257- 261.
26. Chira C, Vereșezan O, **Kacsó G**. Three-dimensional Conformal Radioterapy for treatment of localized prostate adenocarcinoma: the Ion Chiricuta Cancer Center Experience. *J Radioth Med Oncol*, 2008; 1: 32-39.
27. Muntean A, Muresan A, Mihailov A, Nagy V, **Kacsó G**, Ghilezan N. Concomitent Preoperative Chemoradiotherapy with Capecitabine in Locally Advanced Rectal adenocarcinoma: a phase II study. *J Radioth Med Oncol*, 2008; 1: 104- 110.
28. Marina O, **Kacsó G**. Biphosponates in Metastatic Prostate Cancer. *J Radioth Med Oncol*, 2008; 1: 117- 120.
29. Rădulescu M, **Kacsó G** Brahiterapia cu implant permanent de iod 125 în cancerul prostatic nonmetastatic. *Noutatea Medicală*, 2008;4: 287- 296.
30. **Kacsó G**, Fekete Zs. Adjuvant partial breast radiotherapy for early breast cancer-ready for a change? *J BUON* 2008; 13:169- 75 (**BDI**).
31. **Kacsó G**, Fekete Zs. Brachytherapy for soft tissue sarcoma-a forgotten technique? *Radioth Med Oncol*, 2009; 2: 75- 83.
32. Barbus R, Rancea A, Sparchez Z, Fetica B, **Kacso G**. Malignant melanoma of anal canal: a case report. *J Contemporary Brachytherapy* 2009;3:151-3.(**BDI**)
33. Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, **Kacso G**, Andrieu JM. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? *BJU Int*. 2009 Jun;103(12):1641-6. (**ISI, IF=2.865**).
34. Tomuleasa C, Soritau O, Rus-Ciuca D, Pop T, Todea D, Mosteanu O, Pinteia B, Foris V, Susman S, **Kacsó G**, Irimie A. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. *J Gastrointestin Liver Dis*. 2010 Mar;19(1): 61-7. (**ISI, IF=1.43**).
35. Sorițău O, Tomuleasa CI, Páll E, Virág P, Fischer-Fodor E, Foris V, Barbos O, Tatomir C, **Kacsó G**, Irimie A. Enhanced chemoresistance and tumor sphere formation as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer. *Rom J Morphol Embryol*. 2010;51(2): 259-64.(**ISI, IF=0.381**).

36. Tomuleasa C, **Kacsó G**, Sorișău O, Sușman S, Irimie A, Virág P. Cellular interactions in prostate cancer genesis and dissemination. Looking beyond the obvious. *Rom J Morphol Embryol.* 2010;51(3): 427- 435 (**ISI, IF=0.381**).
37. Istrate S, **Kacsó G**, Straciuc O, Miloiu M. Atypical pelvic relapse 6 years after radical surgery and adjuvant radiotherapy for stage I B2 cervix cancer. *J Radiat & Med Oncol* 2010; 16 (2): 98- 101.
38. Craciun M, Lenghel A, Kacso I, **Kacsó G** Early Stage Lung Cancer Diagnosis by Paraneoplastic Nephrotic Syndrome. *J Radiat & Med Oncol* 2010; 16 (3): 148- 152.
39. **Kacsó G**. Report on ESTRO 29. *J Radiat & Med Oncol* 2010; 16 (3): 159- 164.
40. Tomuleasa C, Foris V, Soritau O, Pall E, Dicu T, Lung-Illes V, Brie I, **Kacsó G**. DNA damage and cell governing dynamics of stem cell radiobiology. *Annals of RSCB*, 2010, 14(2): 13-20 (**BDI**)
41. Burz C, Berindan-Neagoe I, Balacescu O, Todor N, Pelau D, Floares C, **Kacsó G**, Tanaselia C, Ursu M, Vlase L, Leucuta SE, Cristea V, Irimie A. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters. *J BUON.* 2010 Apr-Jun;15(2): 263-9 (**ISI, IF=0.48**).
42. Tomuleasa C, Soritau O, Brie I, Pall E, Foris V, Dicu T, Virag P, Irimie A, **Kacsó G**. Mesenchymal stem cell irradiation in culture engages differential effect of hyperfractionated radiotherapy for head and neck cancers. *J BUON* 2010 Apr-Jun;15(2):348-56(**ISI, IF=0.48**).
43. Tomuleasa C, Soritau O, Rus-Ciucă D, Ioani H, Susman S, Petrescu M, Timis T, Cernea D, **Kacsó G**, Irimie A, Florian IS. Functional and molecular characterization of glioblastoma multiforme- derived cancer stem cells. *J BUON.* 2010 Jul-Sep;15(3): 583-91 (**ISI, IF=0.48**).
44. Spârchez Z, Radu P, Zaharia T, **Kacsó G**, Grigorescu I, Badea R. Contrast enhanced ultrasound guidance: a new tool to improve accuracy in percutaneous biopsies. *Med Ultrason.* 2010 Jun;12(2):133-8 (**ISI, IF=0**)
45. Tomuleasa C, Soritau O, **Kacsó G**, Fischer-Fodor E, Cocis A, Ioani H, Timis T, Petrescu M, Cernea D, Virag P, Irimie A, Florian IS. Arsenic trioxide sensitizes cancer stem cells to chemoradiotherapy. A new approach in the treatment of inoperable glioblastoma multiforme. *J BUON.* 2010;15(4):758-62 (**ISI, IF=0.48**).
46. Sparchez Z, Radu P, Zaharia T, **Kacsó G**, Diaconu B, Grigorescu I, Badea R. B-mode and contrast enhanced ultrasound guided biopsy of portal vein thrombosis. Value in the diagnosis of occult hepatocellular carcinoma in liver cirrhosis. *Med Ultrason.* 2010 Dec;12(4):286-94 (**ISI, IF=0**)
47. Florian IS, Tomuleasa C, Soritau O, Timis T, Ioani H, Irimie A, **Kacsó G**. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy. *JBUON* 2011; 16 (1):16-23 (**ISI, IF=0.607**).
48. Tomuleasa C, Sușman S, Sorișău O, Moșteanu O, Pop T, Petrushev B, **Kacsó G**, Buigă R, Tanțău M, Irimie A. Stem-like cells in colorectal oncology. *Rom J Intern Med.* 2011;49(3):189-96 (**BDI**)
49. Petrushev B, Tomuleasa C, Sușman S, Sorișău O, Aldea M, **Kacsó G**, Buigă R, Irimie A. The axis of evil in the fight against cancer. *Rom J Intern Med.* 2011;49(4):319-25 (**BDI**)
50. Sparchez Z, Radu P, Zaharia T, **Kacsó G**, Grigorescu I, Botis G, Badea R. Usefulness of contrast enhanced ultrasound guidance in percutaneous biopsies of liver tumors. *J Gastrointestin Liver Dis.* 2011 Jun;20(2):191-6 (**ISI, IF=1.81**).
51. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, **Kacsó G**, Florian IS. Metformin plus temozolomide-

- based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. *J BUON*. 2011 Apr-Jun;16(2):282-9 (**ISI, IF=0.607**).
52. Tomuleasa C, **Kacsó G**, Soritau O, Susman S, Petrushev B, Aldea M, Buiga R, Irimie A. The fundamental mechanisms of metastatic spread and chemotherapy resistance in lung cancer *Pneumologia*. 2011 Apr-Jun;60(2):99-103 (**BDI**)
 53. Aldea M, Tomuleasa C, Petrushev B, Susman S, **Kacsó G**, Irimie A, Florian IS, Soritau O. Antidiabetic pharmacology: a link between metabolic syndrome and neuro-oncology? *J BUON*. 2011 Jul-Sep;16(3):409-13. (**ISI, IF=0.607**).
 54. Tomuleasa C, Soritau O, Fischer-Fodor E, Pop T, Susman S, Mosteanu O, Petrushev B, Aldea M, Acalovschi M, Irimie A, **Kacsó G**. Arsenic trioxide plus cisplatin/interferon α -2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. *Hematol Oncol Stem Cell Ther* 2011; 4(2):60-6 (**BDI**)
 55. **Kacsó G**. Osteoclast targeted therapy in prostate cancer. *J Radiat & Med Oncol* 2011; 17(2): 90-93.
 56. Kacso I, Lenghel A, Bondor CI, Moldovan D, Rusu C, Nita C, Hancu N, Caprioara MG, **Kacsó G**. Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio in type 2 diabetes patients. *Int Urol Nephrol* 2012; 44(4): 1151-7. (**ISI, IF 1.325**)
 57. Kacso I, Bondor CI, **Kacsó G**. Plasma adiponectin is related to the progression of kidney disease in type 2 diabetes patients. *Scand J Clin Lab Invest* 2012; 72: 333-339. (**ISI, IF=1.294**)
 58. Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, **Kacsó G**, Berindan I, Irimie A, Cristea V. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. *Exp Oncol*. 2012;34(1):17-24. (**BDI**)
 59. Kacso IM, Trifa AP, Popp RA, **Kacsó G**. Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients. *Int Urol Nephrol* 2012; 44(6):1771-7 (**ISI, IF 1.325**)
 60. Tomuleasa C, Soritau O, Orza A, Dudea M, Petrushev B, Mosteanu O, Susman S, Florea A, Pall E, Aldea M, **Kacsó G**, Cristea V, Berindan-Neagoe I, Irimie A. Gold nanoparticles conjugated with cisplatin/ doxorubicin/ capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells. *J Gastrointestin Liver Dis*. 2012 Jun;21(2):187-9. (**ISI, IF=1.855**).
 61. Kacso IM , Bondor CI, **Kacsó G**. Soluble serum Klotho in diabetic nephropathy: Relationship to VEGF-A. *Clin Biochem* 2012; 45 (16-17): 1415-20. ((**IF=2.450**)).
 62. Kacso IM, **Kacsó G** Endothelial cell-selective adhesion molecule in diabetic nephropathy. *Eur J Clin Invest* 2012; 42(11):1227-34. (**ISI, IF=3.365**).
 63. Sparchez Z, Radu P, **Kacsó G**, Eniu D, Hica S, Sparchez M. Contrast-enhanced ultrasound guided biopsy of superficial toraco-abdominal and neck lesions. Initial experience in 20 patients. *Med Ultrason*. 2012 Dec;14(4):288-93. (**ISI, IF=0**)
 64. Kacso IM, Bondor CI, **Kacsó G** Low serum endothelial cell-selective adhesion molecule predicts increase in albuminuria in type 2 diabetes patients. *Int Urol Nephrol*. 2013 (**ISI, IF 1.293**)
 65. Kacso IM, Potra AR, Rusu A, Moldovan D, Rusu CC, **Kacsó G**, Hancu ND, Muresan A, Bondor C. Relationship of endothelial cell selective adhesion molecule to markers of oxidative stress in type 2 diabetes. *Scand J Clin Lab Invest*. 2014 Mar;74(2):170-6. ((**IF 1.899**))
 66. Aldea M, Craciun L, Tomuleasa C, Berindan-Neagoe I, **Kacsó G**, Florian IS, Crivii C. Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery. *Tumour Biol*. 2014 Jun;35(6):5101-10. (**IF 2.94**)

67. Cathomas R, Bajory Z, Bouzid M, El Ghoneimy A, Gillessen S, Goncalves F, **Kacsó G**, Kramer G, Milecki P, Pacik D, Tantawy W, Lesniewski-Kmak K. Management of bone metastases in patients with castration-resistant prostate cancer. *Urol Int.* 2014;92(4):377-86. (ISI, IF 1.426)
68. Nemes A, Tomuleasa C, **Kacsó G**. The androgen receptor remains a key player in metastatic hormone-refractory prostate cancer. Implications for new treatments. *J BUON.* 2014 Apr-Jun;19(2):357-64 (ISI, IF 0.741).
69. Aldea MD, Petrushev B, Soritau O, Tomuleasa CI, Berindan-Neagoe I, Filip AG, Chereches G, Cenariu M, Craciun L, Tatomir C, Florian IS, Crivii CB, **Kacsó G** Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells. *J BUON.* 2014 Apr-Jun;19(2):502-11 (IF 0.741)
70. Galdau, B, Pislă D, **Kacsó G**, et al. New design of br-1: an innovative parallel robot for brachytherapy, Edited by: Popescu, D; ISI Proceedings ICPR-AEM 2014, 206-211. (ISI)
71. **Kacsó G**, Hantila IF, Drosu OM, Maricaru M, Stanculescu M. Qualitative analysis of the temperature field produced by an early stage tumor. *Revue Roumaine des Sciences Techniques – serie electrotechnique et energetique*, 2014: 59 (4):433-443, (ISI, IF 0.386)
72. **Kacsó G**, Hantila IF, Vasilescu M, Drosu O, Maricaru M, Stanculescu M The thermal field of an early breast cancer reflected on the breast surface. (ISI) **proceedings**: 2014 International symposium on fundamental electrical engineering. 2014 (nov) ISBN 978-1-4799-6821-3 (ISI).
73. Spârchez Z, Radu P, Spârchez M, Crisan N, **Kacso G**, Petrut B. Contrast enhanced ultrasound of renal masses. A reappraisal of EFSUMB recommendations and possible emerging applications. *Med Ultrason* 2015 Jun;17(2):219-26 (ISI, IF 1.167), ISSN:2066- 8643.
74. Kacso IM, Potra AR, Bondor CI, Moldovan D, Rusu C, Patiu IM, Racasan S, Orasan R, Vladutiu D, Spanu C, Rusu A, Nita C, Moldovan R, Ghigolea B, **Kacso G**. Adiponectin predicts cardiovascular events in diabetes dialysis patients. *Clin Biochem.* 2015 Sep;48(13-14):860-5. (ISI, IF 2.382), ISSN:0009-9120.
75. Popescu T, Kacsó AC, Pislă D, **Kacsó G**. Brachytherapy next generation : robotic systems. *J Contemp Brachytherapy.* 2015 Dec;7(6):510-4. Dec 30. (ISI, IF 1,413)
76. Spârchez Z, Radu P, **Kacsó G**, Spârchez M, Zaharia T, Al Hajjar N. Prospective comparison between real time contrast enhanced and conventional ultrasound guidance in percutaneous biopsies of liver tumors. *Med Ultrason* 2015 Dec;17(4):456-63. ISSN:2066- 8643.
77. Aldea M, Florian IA, **Kacsó G**, Craciun L, Boca S, Soritau O, Florian IS. Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma. *Pharm Res.* 2016 Sep;33(9):2059-77. (IF=3.002)
78. **Kacsó G**, Hantila IF, Vasilescu M, Drosu O, Maricaru M. Using a thermal sensing bra in early locating the breast tumors. *Rev. Roum. Sci. Techn.– Électrotechn. et Énerg* 2016; 61(1):89-93. (ISI, IF 1.36)
79. Vasilescu GM, Cauni V, **Kacsó G**, et al. Issues on early cancer detection using thermographic methods. 10th International Symposium on Advanced Topics in Electrical Engineering (ATEE). 2017: 283–286. (ISI Proceedings) <https://doi.org/10.1109/ATEE.2017.7905121>
80. Nenu I, Gafencu GA, Popescu T, **Kacsó G**. Lactate - A new frontier in the immunology and therapy of prostate cancer. *J Cancer Res Ther* 2017 Jul-Sep;13(3):406-411 (ISI, IF=0.842)

81. Eisenberger M, Hardy-Bessard AC, Kim CS, Géczi L, Ford D, Mourey L, Carles J, Parente P, Font A, **Kacsó G**, Chadjaa M, Zhang W, Bernard J, de Bono J. Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m²) and the Currently Approved Dose (25 mg/m²) in Postdocetaxel Patients with Metastatic Castration-Resistant Prostate Cancer-PROSELICA. *J Clin Oncol*. 2017 Oct 1;35(28):3198-3206. (**ISI, IF=26.36**)
82. Aldea M, Potara M, Soritau O, Stefan Florian I, Florea A, Nagy-Simon T, Pileczki V, Brie I, Maniu D, **Kacsó G**. Chitosan-capped gold nanoparticles impair radioresistant glioblastoma stem-like cells. *JBUON* 2018; 23 (3): 800-813. (**ISI, IF=1.766**)